Establishment Labs (ESTA) | Financial Analysis & Statements
Establishment Labs Holdings Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
64.6M
Gross Profit
45.5M
70.46%
Operating Income
-3.9M
-6.08%
Net Income
-2.6M
-4.05%
EPS (Diluted)
$-0.09
Balance Sheet Metrics
Total Assets
357.2M
Total Liabilities
333.6M
Shareholders Equity
23.5M
Debt to Equity
14.17
Cash Flow Metrics
Operating Cash Flow
7.0M
Free Cash Flow
-1.8M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Establishment Labs Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 211.1M | 166.0M | 165.2M | 161.7M | 126.7M |
| Cost of Goods Sold | 64.8M | 56.5M | 58.2M | 55.1M | 41.3M |
| Gross Profit | 146.3M | 109.5M | 107.0M | 106.6M | 85.4M |
| Gross Margin % | 69.3% | 66.0% | 64.8% | 65.9% | 67.4% |
| Operating Expenses | |||||
| Research & Development | 20.2M | 19.7M | 26.4M | 20.3M | 18.3M |
| Selling, General & Administrative | 165.1M | 139.8M | 145.6M | 126.0M | 92.2M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 185.3M | 159.5M | 172.0M | 146.3M | 110.5M |
| Operating Income | -39.0M | -50.0M | -65.0M | -39.7M | -25.1M |
| Operating Margin % | -18.5% | -30.1% | -39.4% | -24.5% | -19.8% |
| Non-Operating Items | |||||
| Interest Income | 423.0K | 1.5M | 1.0M | 87.0K | 23.0K |
| Interest Expense | 25.3M | 20.8M | 15.4M | 11.8M | 9.1M |
| Other Non-Operating Income | 5.8M | -15.3M | 816.0K | -21.5M | -5.5M |
| Pre-tax Income | -58.0M | -84.6M | -78.6M | -72.8M | -39.7M |
| Income Tax | -7.0M | -32.0K | -81.0K | 2.4M | 1.4M |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -51.1M | -84.6M | -78.5M | -75.2M | -41.1M |
| Net Margin % | -24.2% | -51.0% | -47.5% | -46.5% | -32.5% |
| Key Metrics | |||||
| EBITDA | -22.3M | -56.2M | -58.3M | -38.4M | -27.3M |
| EPS (Basic) | $-1.72 | $-3.00 | $-3.07 | $-3.08 | $-1.72 |
| EPS (Diluted) | $-1.72 | $-3.00 | $-3.07 | $-3.08 | $-1.72 |
| Basic Shares Outstanding | 29620022 | 28161761 | 25600029 | 24457793 | 23972722 |
| Diluted Shares Outstanding | 29620022 | 28161761 | 25600029 | 24457793 | 23972722 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Establishment Labs Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 75.6M | 90.3M | 40.0M | 66.4M | 53.4M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 77.5M | 65.0M | 46.9M | 35.4M | 24.4M |
| Inventory | 85.6M | 78.8M | 79.5M | 36.6M | 28.4M |
| Other Current Assets | 2.5M | 2.6M | 2.4M | 1.6M | 1.8M |
| Total Current Assets | 249.9M | 243.0M | 174.9M | 149.9M | 113.3M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 4.3M | 5.6M | 3.4M | 3.7M | 2.2M |
| Goodwill | 12.4M | 14.1M | 8.9M | 5.5M | 5.3M |
| Intangible Assets | 9.9M | 11.7M | 8.0M | 4.6M | 4.4M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 16.1M | 7.3M | 4.7M | 1.3M | 558.0K |
| Total Non-Current Assets | 107.2M | 103.8M | 93.7M | 61.2M | 26.3M |
| Total Assets | 357.2M | 346.8M | 268.6M | 211.1M | 139.5M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 43.1M | 44.8M | 41.6M | 20.0M | 14.5M |
| Short-term Debt | 14.1M | 1.5M | 773.0K | 688.0K | 402.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.8M | 1.7M | - | - | - |
| Total Current Liabilities | 82.1M | 68.3M | 57.2M | 39.0M | 31.9M |
| Non-Current Liabilities | |||||
| Long-term Debt | 250.3M | 223.8M | 191.5M | 178.7M | 53.8M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | 102.0K | 147.0K | -44.0K | - |
| Total Non-Current Liabilities | 251.5M | 225.5M | 193.1M | 180.3M | 56.9M |
| Total Liabilities | 333.6M | 293.7M | 250.2M | 219.2M | 88.8M |
| Equity | |||||
| Common Stock | 433.4M | 420.4M | 315.6M | 223.6M | 219.7M |
| Retained Earnings | -495.8M | -444.7M | -360.1M | -281.6M | -206.4M |
| Treasury Stock | 2.9M | 2.9M | 2.9M | 2.9M | 2.9M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 23.5M | 53.1M | 18.4M | -8.2M | 50.7M |
| Key Metrics | |||||
| Total Debt | 264.5M | 225.3M | 192.2M | 179.3M | 54.2M |
| Working Capital | 167.8M | 174.8M | 117.8M | 110.9M | 81.4M |
Balance Sheet Composition
Establishment Labs Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -51.1M | -84.6M | -78.5M | -75.2M | -41.1M |
| Depreciation & Amortization | 10.5M | 7.6M | 4.9M | 4.3M | 4.1M |
| Stock-Based Compensation | 11.8M | 15.4M | 14.9M | 13.4M | 10.4M |
| Working Capital Changes | -16.9M | -20.0M | -35.1M | -19.9M | -9.6M |
| Operating Cash Flow | -50.8M | -72.0M | -87.9M | -72.8M | -34.8M |
| Investing Activities | |||||
| Capital Expenditures | -6.0M | -6.1M | -7.9M | -2.9M | -2.4M |
| Acquisitions | -307.0K | -50.0K | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -6.4M | -6.2M | -7.9M | -3.4M | -2.9M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 24.5M | 24.5M | 0 | 168.1M | 0 |
| Debt Repayment | -1.0M | 0 | 0 | -71.7M | -175.0K |
| Financing Cash Flow | 31.8M | 123.4M | 84.1M | 96.4M | -531.0K |
| Free Cash Flow | -57.6M | -74.1M | -113.1M | -86.4M | -34.3M |
| Net Change in Cash | -25.3M | 45.3M | -11.7M | 20.2M | -38.2M |
Cash Flow Trend
Establishment Labs Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-37.89
Forward P/E
316.35
Price to Book
79.68
Price to Sales
8.92
PEG Ratio
0.41
Profitability Ratios
Profit Margin
-24.19%
Operating Margin
-6.08%
Return on Equity
-133.25%
Return on Assets
-6.93%
Financial Health
Current Ratio
3.04
Debt to Equity
1,123.15
Beta
1.08
Per Share Data
EPS (TTM)
$-1.72
Book Value per Share
$0.80
Revenue per Share
$7.13
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ESTA | 1.9B | -37.89 | 79.68 | -133.25% | -24.19% | 1,123.15 |
| Abbott Laboratories | 160.7B | 25.97 | 3.09 | 12.36% | 13.90% | 26.79 |
| Stryker | 126.3B | 39.21 | 5.62 | 15.08% | 12.92% | 72.97 |
| Axogen | 1.9B | -110.18 | 13.15 | -13.49% | -6.97% | 55.50 |
| Artivion | 1.8B | 179.71 | 4.03 | 2.70% | 2.21% | 57.67 |
| AdaptHealth | 1.7B | 16.64 | 1.11 | -4.25% | -2.18% | 124.67 |
Financial data is updated regularly. All figures are in the company's reporting currency.






